Solid Pancreatic Tumor
Conditions
Brief summary
Currently, the best way to evaluate pancreatic masses is through endoscopic-guided needle sampling of the mass to determine the diagnosis by looking at the acquired tissue under a microscope. This is done by inserting a small camera (endoscope) through the mouth of the patient then advanced to the stomach and using ultrasound guidance a sample of the pancreas can be acquired through the stomach. The sampling is usually done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed immediately under the microscope and can give feedback to the endoscopist until enough cells has been acquired for a diagnosis. This method has been shown to increase the ability to diagnose pancreatic cancer but is expensive and requires significant amount of resources. New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology) and has been shown to be also very accurate in the diagnosis of pancreatic cancer. The purpose of this study is to compare endoscopy-guided biopsy of pancreatic masses with the new core needle (FNB), which can obtain more tissue for diagnosis vs. using a traditional needle (FNA) with the help of an immediate assessment of the obtained samples under the microscope to determine whether enough tissue has been obtained (ROSE). Both approaches have been shown to increase the accuracy of diagnosis in solid pancreatic masses but it is unclear which one is superior. This is a randomized trial meaning that the participants would either undergo biopsy with the new needle or with the traditional needle plus the addition of on-site assessment of the obtained samples. The advantage of the new needle is that it is easy to implement and likely much cheaper. If the investigators can show in our study that the new needles are as accurate as FNA with ROSE then FNB could be implemented across hospitals worldwide in an easier and less expensive fashion.
Interventions
PROCEDUREEUS
Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
PROCEDUREFNA with ROSE
Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
PROCEDUREFNB alone
Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
Sponsors
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Intervention model description
Procedures are performed with a linear echoendoscope under conscious sedation. EUS-FNB is performed with a 22G or 25G needles Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist. EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. This is a multi-center, randomized, single blinded, non-inferiority, trial comparing EUS-FNB alone to EUS-FNA with ROSE in the diagnosis of solid pancreatic masses. Following consent, patients are randomized, at the time of the procedure, to undergo either EUS-FNB alone or EUS-FNA with ROSE. The randomization sequence will be generated by a computerized randomization scheme using a block size of 10 stratified according to the endoscopist.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Patients referred for EUS evaluation of a definite solid pancreatic mass noted on computed tomography(CT)/Magnetic resonance imaging(MRI)/EUS, in which malignancy is suspected with no previous histological diagnosis
Exclusion criteria
* Age \< 18 years, pregnant patients. * Uncorrectable coagulopathy Prothrombin time (PT) \>50% of control, Partial Thromboplastin time (PTT) \>50 sec, or International normalized ratio (INR) \>1.5 and/or uncorrectable thrombocytopenia platelet count\<50, 000109/L.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic accuracy | 12 months | Defined as (true positive + true negative)/all samples |
| Final diagnosis of malignant pancreatic mass | 10 months | Will be based on the following criteria: * Histological evidence of malignancy on the corresponding subsequent surgical specimen * Presence of an unresectable lesion during subsequent surgery * Malignant cytology/pathology on EUS-sampling followed by documented loco-regional progression/development of metastases on follow-up axial imaging. |
| Final diagnosis of benign pancreatic mass | 10 months | Will be based on the following criteria: * Surgical pathology or exploration showing the absence of malignancy * Follow-up imaging at \> 6 months reporting stability of the pancreatic lesion * Cytological or histopathological diagnosis of benign disease with an appropriate clinical course of disease for minimum of 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Procedural time | 6 to 12 months of data collection and 3 to 6 months of data analysis. | Time spent during the procedure |
| Diagnostic characteristics | 6 to 12 months of data collection and 3 to 6 months of data analysis. | sensitivity, specificity, positive and negative predictive value |
| Rate of procedure-related adverse events | 6 to 12 months of data collection and 3 to 6 months of data analysis. | An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a procedure done, whether or not considered causally related to the procedure. A serious adverse event is an adverse event occurring during the procedure or any time after the procedure, that fulfills one or more of the following criteria: * Results in death * Is immediately life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability or incapacity * Is a congenital abnormality or birth defect * Is an important medical event that may jeopardize the patient or may require medical intervention to prevent one of the outcomes listed above. |
| Specimen adequacy | 6 to 12 months of data collection and 3 to 6 months of data analysis. | Defined as the proportion of samples in which a final histopathological diagnosis could be made |
| Median number of needle passes | 6 to 12 months of data collection and 3 to 6 months of data analysis. | Number of times passing the needle for tissue acquisition |
Countries
Canada
Outcome results
None listed